Compass Pathways plc

Pioneering psychedelic mental health

London, UK

Compass Pathways plc is a biotechnology company focused on accelerating patient access to evidence-based innovation in mental health, pioneering COMP360, an investigational synthetic psilocybin treatment for people with serious mental health conditions, particularly treatment-resistant depression (TRD).

Shareable draft

Check out Compass Pathways plc on @MedStartr Today Compass Pathways plc is a biotechnology company focused on accelerating patient access to evidence-based innovation in mental health, pioneering COMP360, an investigational synthetic psilocybin treatment for people with serious mental health conditions, particularly treatment-resistant depression (TRD). #TreatmentResistantDepressionTRD #PostTraumaticStressDisorder #AnorexiaNervosa #MajorDepressiveDisorder #ChronicClusterHeadache #BodyDysmorphicDisorder #SuicidalIdeation #Depression #MentalHealthConditions #AutismSpectrumDisorder #BehavioralHealthCare #MedMo #MedStartrVentures

https://www.medstartr.ai/s/58N1bFVgtyg

Get Involved in Compass Pathways plc

How We Help

Problem Statement

Addressing serious mental health conditions with high unmet needs and limitations of conventional treatments, Compass Pathways aims to provide rapid and durable responses through novel psychedelic-assisted therapies.

Core Technology

COMP360, an investigational synthetic psilocybin treatment

Key Differentiators

Pioneering a new model of psilocybin therapy integrating its proprietary COMP360 formulation with psychological support; holding FDA Breakthrough Therapy designation and UK Innovative Licensing and Access Pathway (ILAP) designation for TRD; conducting the largest-to-date randomized, controlled, double-blind psilocybin treatment clinical program; emphasizing rapid and durable responses; holding key patents covering COMP360 crystalline psilocybin polymorph A; and a strong commitment to scientific rigor, integrity, and collaboration.

Clinical Focus

Primarily serious mental health conditions with high unmet needs, including Treatment-Resistant Depression (TRD), Post-Traumatic Stress Disorder (PTSD), Anorexia Nervosa, Major Depressive Disorder (MDD), chronic cluster headache, body dysmorphic disorder, suicidal ideation, and autism.

Target Customers

Certified third-party treatment centers

Company Info

Business Model: Pre-commercial stage biotechnology company focused on funding the research and development of its lead drug candidate, COMP360. The future strategy involves commercial sale of its proprietary, single-administration therapy (delivered with psychological support) to certified third-party treatment centers, generating revenue from drug price, session frequency, and payer reimbursement for therapist and clinic services.
Founded: 2016
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: compasspathways.com

Disease Areas

Treatment-Resistant Depression (TRD)Post-Traumatic Stress Disorder Anorexia Nervosa Major Depressive Disorder Chronic Cluster Headache Body Dysmorphic Disorder Suicidal Ideation Depression Mental health conditions Autism Spectrum Disorder

Technologies

Psychedelic MedicinePsilocybin TherapyPsychological SupportProprietary FormulationBiotechnologyClinical Trials

Clinical & IP

🔬

Clinical Validation

COMP360 has successfully completed two pivotal Phase 3 trials (COMP005 & COMP006) for TRD, both meeting primary endpoints with statistically significant and clinically meaningful reductions in depression symptoms. It holds FDA Breakthrough Therapy designation and UK ILAP designation for TRD. A Phase 2b/3 trial for PTSD has been initiated following positive Phase 2 open-label study results, showing safety and rapid, durable improvement.

🛡️

IP Protection

Holds key patents covering its COMP360 crystalline psilocybin polymorph A.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Compass Pathways plc?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.